
Opinion|Videos|June 9, 2025
The importance of studying efficacy and safety of treatment in Black patients with mHSPC
Author(s)Quoc-Dien Trinh, MD, MPH
Research highlights the need for personalized treatment in mHSPC, addressing variations in drug efficacy across diverse populations for optimal patient care.
Advertisement
Episodes in this series

Importance of Personalized Medicine
Key Themes:
- Drug efficacy and safety may vary across different subpopulations.
- Considerations extend beyond race to other demographic factors.
- There is a potential need for personalized dosing approaches.
- Targeted studies are crucial for clinician confidence and patient reassurance.
Key Points for Physicians:
- Consider individual characteristics beyond race when selecting treatments.
- Recognize the growing importance of personalized medicine approaches.
- Communicate clearly with patients about evidence supporting treatment recommendations.
Notable Insights: The discussion of personalized medicine extends beyond race to consider the broader landscape of individual variation in drug response and tolerability.
Clinical Significance: Advancing personalized medicine approaches, including subgroup-specific analyses, will improve cancer care by appropriately tailoring treatments to individual and population characteristics.
Advertisement
Related to this article

Longer-term findings from the phase 2 ARACOG study suggest differences in objectively measured cognitive function between ARPIs.

Engy Habashy, MD, discusses key takeaways from the 2025 AUA GSM guideline, including the role of androgens and hormonal therapies in managing genitourinary syndrome of menopause.

Chad R. Ritch, MD, MBA, FACS, discusses how PSMA-PET informs staging, treatment planning, recurrence workup, and the interpretation of equivocal findings.

Michael S. Cookson, MD, MMHC, FACS, discusses how Anktiva’s expanded FDA approval may broaden bladder-preserving treatment options for BCG-unresponsive papillary-only NMIBC.

Jeffrey M. Spier, MD, discusses how fatigue may impact patient quality-of-life and when dose reduction may be an appropriate treatment strategy.

This approval expands the perioperative use of pembrolizumab plus enfortumab vedotin to all patients with MIBC, regardless of cisplatin eligibility.
Advertisement
Advertisement
Trending on Urology Times
1
How PSMA-PET shapes staging and recurrence workup in prostate cancer
2
ESMO 2026: Key presentations across genitourinary oncology
3
Engy Habashy, MD, on the role of androgens in GSM management
4
European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC
5


